期刊文献+

肿瘤相关巨噬细胞在弥漫大B细胞淋巴瘤免疫微环境中的研究进展

Advances in the study of tumor-associated macrophages in the immune microenvironment of diffuse large B-cell lymphoma
下载PDF
导出
摘要 弥漫大B细胞淋巴瘤(DLBCL)是发病率最高的淋巴瘤亚型。肿瘤相关巨噬细胞(TAMs)是肿瘤微环境(TME)中的重要组成部分,具有促进DLBCL的生长增殖、逃脱机体免疫、降低生存期等一系列作用。鉴于TAMs对DLBCL具有重要的意义,本文就目前有关TAMs对DLBCL免疫微环境中的作用进行简要综述,对TAMs的形成、分类、逆转M2型为M1型以及相关因子的作用机制,预后影响等方面进行了简略总结,并对TAMs相关的分子靶向治疗及新药物等进行简要阐述。 Diffuse large B-cell lymphoma(DLBCL)is the most prevalent subtype of lymphoma.Tumor-associated macrophages(TAMs)have emerged as crucial components of the tumor microenvironment(TME),exerting a series of effects that promote the growth and proliferation of DLBCL,facilitating evasion from the host immune system,and reducing overall survival.Given the significance of TAMs in DLBCL,this article provides a brief review of the current study on the role of TAMs in the immune microenvironment of DLBCL,including briefly summarization of the formation and classification of TAMs,phenotypic conversion from M2 to M1 as well as the mechanisms of related factors,and prognostic implications.Furthermore,it briefly discusses the molecular targeted therapies and new drugs related to TAMs.
作者 武文可 贾韬 WU Wenke;JIA Tao(Jinzhou Medical University,Jinzhou,Liaoning 121001,China;Department of Hematology,the First People′s Hospital of Lianyungang,the Affiliated Lianyungang Hospital of Xuzhou Medical University,the First Affiliated Hospital of Kangda College of Nanjing Medical University Lianyungang,Lianyungang,Jiangsu 222000)
出处 《徐州医科大学学报》 CAS 2024年第1期72-78,共7页 Journal of Xuzhou Medical University
基金 江苏省科技项目青年基金项目(BK20190985)。
关键词 弥漫大B细胞淋巴瘤 非霍奇金淋巴瘤 肿瘤微环境 肿瘤相关巨噬细胞 分子靶向治疗 diffuse large B-cell lymphoma non-Hodgkin lymphoma tumor microenvironment tumor-associated macrophages molecular targeted therapy
  • 相关文献

参考文献6

二级参考文献37

  • 1肖水源.《社会支持评定量表》的理论基础与研究应用[J].临床精神医学杂志,1994,4(2):98-100. 被引量:4219
  • 2Cheson BD, Pfistner B, Juweid ME, et al. Revised response crite- ria for malignant lymphoma[ J], J Clin Oneol, 2007, 25(5) : 579- 586. DOI: 10.1200/JCO.2006.09.2403.
  • 3Cheson BD. Role of functional imaging in the management of lym- phoma[J]. J Clin Oneol, 2011, 29(14): 1844-1854. DOI: 10. 1200/JC O. 2010.32.5225.
  • 4Vails L, Badve C, Avril S, et al. FDG-PET imaging in hematologi- cal malignancies [ J ]. Blood Rev, 2016, 30 (4) : 317-331. DOI : 10. lO16/j.hlre.2016.02.003.
  • 5National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oneology: Hodgkin' s Lymphomas (v.2.2016) [ R/ OL]. https ://www. necn. org/professionals/physician _gls/f_guide- lines.asp.
  • 6National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin's Lymphomas (v. 2.2016) [ R/OL]. https://www, nccn. org/professionals/physician_gls/f_ guidelines, asp.
  • 7Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification[ J]. J Clin Oncol, 2014, 32(27) : 3059-3068. DOI : 10.1200/JCO.2013.54.8800.
  • 8Seam P, Juweid ME, Cheson BD. The role of FDG-PET scans in patients with lymphoma[J]. Blood, 2007, 110(10) : 3507-3516. DOI: 10.1182/blood-2007 -06-097238.
  • 9Kostakoglu L, Cheson BD. Current role of FDG PET/CT in lympho-ma[J]. Eur J Nucl Med Mol Imaging, 2014, 41(5) : 1004-1027. DOI : 10.1007/s00259-013-2686-2.
  • 10Zinzani PL, Stefoni V, Tani M, et al. Role of [ JSF] fluorodeox- yglucose positron emission tomography scan in the follow-up of lym- phoma[J]. J Clin Oncol, 2009, 27(11): 1781-1787. DOI:10. 1200/JCO.2008.16.1513.

共引文献56

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部